Clinical Trial

Myeloma Registry Platform (MYRIAM)

Study acronym: MYRIAM
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2017-10-11; most recent amendment 2026-07-10.
Trial Details
NCT Number NCT03308474
Lead Sponsor iOMEDICO AG
Collaborators: Deutsche Studiengruppe Multiples Myelom (DSMM)
Conditions Multiple Myeloma
Enrollment 2,200 participants
Start Date 2017-09-25
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-13